Crossmark

Aspartate is an endogenous metabolic limitation for tumour growth

Crossref DOI link: https://doi.org/10.1038/s41556-018-0125-0

Published Online: 2018-06-25

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sullivan, Lucas B. https://orcid.org/0000-0002-6745-8222
Luengo, Alba

Danai, Laura V.

Bush, Lauren N.

Diehl, Frances F.

Hosios, Aaron M.

Lau, Allison N.

Elmiligy, Sarah

Malstrom, Scott

Lewis, Caroline A. https://orcid.org/0000-0003-1787-5084
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
License Information

Text and Data Mining valid from 2018-06-25
More Information

Article History

Received: 15 February 2018

Accepted: 18 May 2018

First Online: 25 June 2018

Competing interests

: M.G.V.H. is a consultant and scientific advisory board member for Agios Pharmaceuticals and Aeglea Biotherapeutics.